Morgan Stanley raised the firm’s price target on CME Group (CME) to $340 from $319 and keeps an Overweight rating on the shares. Amid renewed macro and credit concerns, the firm sees CME extending its futures exchange moat and paving way for new growth vectors that are not yet in the price, such as prediction markets, tokenization, 24/7 trading, and crypto, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CME:
- CME Group: Resilient Fee-Based Franchise with Defensive Strengths and Underappreciated Structural Growth Justifies Buy Rating
- CME Group price target raised to $312 from $304 at Barclays
- CME Group reports Q4 adjusted EPS $2.77, consensus $2.74
- These Are the Stocks Reporting Earnings Today – February 4, 2026
- CME Group reports January average daily volume 29.6M contracts